BOSTON ( TheStreet) -- Welcome 2010! To get the year started, here's a calendar of important, potentially stock-moving biotech events for January:
28th Annual J.P. Morgan Healthcare Conference.
Food and Drug Administration advisory committee meeting for Forest Labs' Bystolic in congestive heart failure.
International Association for the Study of Lung Cancer meeting. Jan. 14
Ilumina (ILMN) investor/analyst meeting. Jan. 16
FDA approval decision date for Mannkind's (MNKD) Afresa, an inhaled insulin for diabetes. Jan. 18
FDA approval decision date for OSI Pharmaceuticals' (OSIP) Tarceva in first-line (maintenance) non-small cell lung cancer. Jan. 22
FDA approval decision date for Acorda Therapeutics' (ACOR) Amaya for multiple sclerosis Jan. 22-24
American Society for Clinical Oncology Gastrointestinal Cancers Symposium. Important clinical trials with potential data readouts or other biotech events expected in January: Spectrum Pharmaceuticals (SPPI) meeting with FDA to discuss complete response letter for colon cancer drug Fusilev. FDA approval decision for Novo Nordisk's (NVO) diabetes drug Victoza. FDA approval decision for Auxillium Pharmaceuticals' (AUXL) Xiaflex for Dupuytren's Contracture. (With Pfizer (PFE) as marketing partner.) Synta Pharmaceuticals (SNTA) --
Results from a phase II study of apilimod in rheumatoid arthritis. -- Reported by Adam Feuerstein in Boston.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV